420 related articles for article (PubMed ID: 4039568)
1. Progestogens with antimineralocorticoid activity.
Losert W; Casals-Stenzel J; Buse M
Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
[TBL] [Abstract][Full Text] [Related]
2. Mespirenone and other 15,16-methylene-17-spirolactones, a new type of steroidal aldosterone antagonists.
Losert W; Bittler D; Buse M; Casals-Stenzel J; Haberey M; Laurent H; Nickisch K; Schillinger E; Wiechert R
Arzneimittelforschung; 1986 Nov; 36(11):1583-600. PubMed ID: 3028435
[TBL] [Abstract][Full Text] [Related]
3. Potassium prorenoate: a new steroidal aldosterone antagonist.
Hofmann LM; Chinn LJ; Pedrera HA; Krupnick MI; Suleymanov OD
J Pharmacol Exp Ther; 1975 Aug; 194(2):450-6. PubMed ID: 1151770
[TBL] [Abstract][Full Text] [Related]
4. The renal action of spirorenone and other 6 beta,7 beta; 15 beta,16 beta-dimethylene-17-spirolactones, a new type of steroidal aldosterone antagonists.
Casals-Stenzel J; Buse M; Wambach G; Losert W
Arzneimittelforschung; 1984; 34(3):241-6. PubMed ID: 6329237
[TBL] [Abstract][Full Text] [Related]
5. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity.
Muhn P; Fuhrmann U; Fritzemeier KH; Krattenmacher R; Schillinger E
Ann N Y Acad Sci; 1995 Jun; 761():311-35. PubMed ID: 7625729
[TBL] [Abstract][Full Text] [Related]
6. Aldosterone antagonism studies in the rhesus monkey.
Hofmann LM; Pedrera HA; Suleymamov OD
J Pharmacol Exp Ther; 1977 Jul; 202(1):216-20. PubMed ID: 406381
[TBL] [Abstract][Full Text] [Related]
7. Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone.
Oelkers W
Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():17-24. PubMed ID: 11246598
[TBL] [Abstract][Full Text] [Related]
8. Extinction of mineralocorticoid effects in 19-norprogesterone derivatives: structure-activity relationships.
Paris J; Botella J; Fournau P; Bonnet P; Thevenot R
J Pharmacol Exp Ther; 1987 Oct; 243(1):288-91. PubMed ID: 2822901
[TBL] [Abstract][Full Text] [Related]
9. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women.
Oelkers W; Berger V; Bolik A; Bähr V; Hazard B; Beier S; Elger W; Heithecker A
J Clin Endocrinol Metab; 1991 Oct; 73(4):837-42. PubMed ID: 1890155
[TBL] [Abstract][Full Text] [Related]
10. Effects of drospirenone on cardiovascular markers in human aortic endothelial cells.
Seeger H; Wallwiener D; Mueck AO
Climacteric; 2009 Feb; 12(1):80-7. PubMed ID: 18979300
[TBL] [Abstract][Full Text] [Related]
11. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models.
Muhn P; Krattenmacher R; Beier S; Elger W; Schillinger E
Contraception; 1995 Feb; 51(2):99-110. PubMed ID: 7750297
[TBL] [Abstract][Full Text] [Related]
12. The influence of endogenous mineralocorticoids on the composition of fetal urine.
Kairaitis K; Lumbers ER
J Dev Physiol; 1990 Jun; 13(6):347-51. PubMed ID: 2084194
[TBL] [Abstract][Full Text] [Related]
13. Detection and comparative evaluation of aldosterone antagonists in glucocorticoid-treated, adrenalectomized rats.
Casals-Stenzel J; Buse M; Losert W
Eur J Pharmacol; 1982 May; 80(1):37-45. PubMed ID: 7095004
[TBL] [Abstract][Full Text] [Related]
14. Excretion of electrolytes in Brown Norway and Fischer 344 rats: effects of adrenalectomy and of mineralocorticoid and glucocorticoid receptor ligands.
Marissal-Arvy N; Mormède P
Exp Physiol; 2004 Nov; 89(6):753-65. PubMed ID: 15364879
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone stimulation of riboflavin incorporation into rat renal flavin coenzymes and the effect of inhibition by riboflavin analogues on sodium reabsorption.
Trachewsky D
J Clin Invest; 1978 Dec; 62(6):1325-33. PubMed ID: 748381
[TBL] [Abstract][Full Text] [Related]
16. Azolimine: a nonsteroidal antagonist of the effects of mineralocorticoids on renal electrolyte excretion.
Gussin RZ; Ronsberg MA; Stokey EH; Cummings JR
J Pharmacol Exp Ther; 1975 Oct; 195(1):8-15. PubMed ID: 1181406
[TBL] [Abstract][Full Text] [Related]
17. Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.
Dahlöf CG; Lundborg P; Persson BA; Regårdh CG
Drug Metab Dispos; 1979; 7(2):103-7. PubMed ID: 38071
[No Abstract] [Full Text] [Related]
18. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
19. Development of a simplified assay for determination of the antimineralocorticoid activity of compounds dosed in rats.
Brandish PE; Chen H; Szczerba P; Hershey JC
J Pharmacol Toxicol Methods; 2008; 57(2):155-60. PubMed ID: 18304838
[TBL] [Abstract][Full Text] [Related]
20. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone.
Oelkers W
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():19-26; discussion 42-3. PubMed ID: 12659403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
